IndraLab

Statements

USP10 deubiquitinates FLT3. 1 / 2

1 | 1

reach

"However, in acute myeloid leukemia (AML) patients with activating mutations in FMS‐like tyrosine kinase 3 (FLT3), USP10 deubiquitinates and stabilizes FLT3 by removing the proteolytic polyubiquitin chains and preventing FLT3 degradation, to aggravate tumor progress (Weisberg et al., 2017)."

31721429

INDRA sources:

Colored badges next to statement headings correspond to evidence counts from knowledge sources, as shown below. Badges to the left of the | separator correspond to curated knowledge base sources, and badges to the right of it correspond to machine reading systems.

IndraLab

Statements

USP10 deubiquitinates FLT3. 1 / 2

INDRA sources:

Databases

Reading